ClinicalTrials.gg
CompletedNCT02013817Updated Aug 18, 2017Results posted

CHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy

A Phase 2 interventional study of rituximab [MabThera/Rituxan] and fludarabine in Lymphocytic Leukemia, Chronic, sponsored by Hoffmann-La Roche. Completed at 8 sites in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-18.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 8 years 1 month after the study started (first participant enrolled Oct 2005, registered Dec 2013).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
43
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 197 studies testing rituximab in Leukemia, Lymphocytic, Chronic, B-Cell — 3 open to participants now, 12 under way, 4 of them phase 3. Rituximab · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
87th of 189
43 · median 39
Started
2005
with 19 others
Phase 2
119 of 197
1 open now
Registered
168th of 197
by date
Lead sponsor
9 of 197
Hoffmann-La Roche

Among the 197 studies testing rituximab in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 87th largest by enrollment of the 189 interventional ones that give a count, is one of 20 that started in 2005, is one of 119 in phase 2, and was the 168th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

3 of the 197 studies testing rituximab in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 197 studies testing rituximab in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of intense combination treatment including MabThera/Rituxan (rituximab), followed by MabThera/Rituxan maintenance therapy in patients with B-cell CLL who are naive to chemotherapy. The anticipated time on study treatment is 2.5 years.

03

Conditions studied

  • Lymphocytic Leukemia, Chronic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, >/= 18 years of age
  • B-cell CLL
  • No previous chemotherapy, radiotherapy, or immunotherapy

Exclusion criteria

Exclusion Criteria:

  • Reduced organ function, or bone marrow dysfunction not due to CLL
  • Patients with a history of other within 2 years prior to study entry, except for adequately treated cancer in situ of the cervix, or basal or squamous cell skin cancer
  • Patients with a history of severe cardiac disease.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    MabThera/Rituxan

    Drug: rituximab [MabThera/Rituxan] · Drug: fludarabine · Drug: cyclophosphamide

Interventions

  • Drugrituximab [MabThera/Rituxan]

    Drug page: Rituximab

    Every 4 weeks for 6 cycles of induction, followed by maintenance therapy every 3 months x 8

  • Every 4 weeks, 6 cycles

  • Every 4 weeks, 3 cycles

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Best Clinical Response of Clinical Remission (CR)

    Best clinical response was determined according to the National Cancer Institute (NCI) Clinical and Clinical plus (+) Radiological evaluations by central response assessment. Assessment of response was performed according to the NCI revised guidelines for the diagnosis and treatment of chronic lymphocytic lymphoma (CLL) with additional computerized tomography (CT) scan evaluation of lymphadenopathy. Per NCI guidelines, CR requires all of the following criteria at least 2 months after the last treatment: no lymphadenopathy (Ly)/ hepatomegaly/ splenomegaly/constitutional symptoms; neutrophils greater than (\>)1500 per microliter (/µL), platelets (PL) \>100,000/µL, hemoglobin (Hb) \>11.0 grams per deciliter (g/dL), lymphocytes (LC) (less than) \<4000/µL, bone marrow (BM) sample must be normocellular for age, \<30% LC.

    Time frame: Weeks 1, 5, 9, 12, 13, 17, 21 and 24

Secondary outcomes

  1. Percentage of Participants With the Best Clinical Response by Visit (Clinical Assessment)

    Best clinical response was determined according to the NCI clinical evaluation and through radiological assessment. CR, CRi, CRu, partial remission (PR), partial remission with toxicity associated (PRTox), progressive disease (PD), and stable disease (SD) were evaluated. Assessment of response was performed according to the NCI revised guidelines for the diagnosis and treatment of CLL with additional CT scan evaluation of lymphadenopathy during the treatment period (Radiological). Response assessment for interim (Week 12), end of induction (Week 24) and at Final Staging (4 weeks after last maintenance dose). Last observation carried forward (LOCF) method was used for missing data. Percentages are based on the number of nonmissing observations within each stratum.

    Time frame: Weeks 12 and 24 and at Final Staging (Week 4 after last maintenance dose)

  2. Percentage of Participants With the Best Clinical Response by Visit (Clinical + Radiological Assessment)

    Best clinical response was determined according to the NCI clinical evaluation and through radiological assessment. CR, CRi, CRu, PR, PRTox, PD, and SD were evaluated. Assessment of response was performed according to the NCI revised guidelines for the diagnosis and treatment of CLL with additional CT scan evaluation of lymphadenopathy during the treatment period (Radiological). Response assessment for interim (Week 12), end of induction (Week 24) and at Final Staging (4 weeks after last maintenance dose). LOCF method was used for missing data. Percentages are based on the number of nonmissing observations within each stratum.

    Time frame: Weeks 12 and 24 and at Final Staging (Week 4 after last maintenance dose)

  3. Time to Next Treatment - Percentage of Participants With an Event

    Time to next treatment was calculated as the number of days from either discontinuation of the study drug or the administration of the last dose, until the participants needed next treatment.

    Time frame: Weeks 1, 5, 9, 12, 13, 17, 21 and 24 and every 8 weeks for 64 Weeks and every 6 months

  4. Time to Next Treatment - Time to Event

    Time to next treatment was calculated as the number of days from either discontinuation of the study drug or the administration of the last dose, until the participants needed next treatment.

    Time frame: Weeks 1, 5, 9, 12, 13, 17, 21 and 24 and every 8 weeks for 64 Weeks and every 6 months

  5. Percentage of Participants With Adverse Events (AEs)

    AEs were recorded from the date of first medication administration until 28 days after the last trial medication.

    Time frame: Day 1 of Cycles 1, 2, 3, 4, 5, and 6 to 28 days after the last trial medication.

07

Results

Posted Sep 10, 2014

Participant flow

Participant flow — Overall Study
MilestoneRituximab, Fludarabine, Cyclophosphamide
Started43
Completed16
Not completed27
Withdrew: Adverse event12
Withdrew: Withdrawal by subject4
Withdrew: Death2
Withdrew: Other9

Outcome measures

PrimaryPercentage of Participants With a Best Clinical Response of Clinical Remission (CR)

Best clinical response was determined according to the National Cancer Institute (NCI) Clinical and Clinical plus (+) Radiological evaluations by central response assessment. Assessment of response was performed according to the NCI revised guidelines for the diagnosis and treatment of chronic lymphocytic lymphoma (CLL) with additional computerized tomography (CT) scan evaluation of lymphadenopathy. Per NCI guidelines, CR requires all of the following criteria at least 2 months after the last treatment: no lymphadenopathy (Ly)/ hepatomegaly/ splenomegaly/constitutional symptoms; neutrophils greater than (\>)1500 per microliter (/µL), platelets (PL) \>100,000/µL, hemoglobin (Hb) \>11.0 grams per deciliter (g/dL), lymphocytes (LC) (less than) \<4000/µL, bone marrow (BM) sample must be normocellular for age, \<30% LC.

Time frame:
Weeks 1, 5, 9, 12, 13, 17, 21 and 24
Reported as:
Number · percentage of participants
Percentage of Participants With a Best Clinical Response of Clinical Remission (CR)
percentage of participantsRituximab, Fludarabine, Cyclophosphamide
NCI Clinical73.7 (56.9 to 86.6)
NCI Clinical (including CRu, CRi)94.7 (82.3 to 99.4)
NCI Clinical + Radiological63.2 (46.0 to 78.2)
NCI Clinical + Radiological (including CRu, CRi)78.9 (62.7 to 90.4)
SecondaryPercentage of Participants With the Best Clinical Response by Visit (Clinical Assessment)

Best clinical response was determined according to the NCI clinical evaluation and through radiological assessment. CR, CRi, CRu, partial remission (PR), partial remission with toxicity associated (PRTox), progressive disease (PD), and stable disease (SD) were evaluated. Assessment of response was performed according to the NCI revised guidelines for the diagnosis and treatment of CLL with additional CT scan evaluation of lymphadenopathy during the treatment period (Radiological). Response assessment for interim (Week 12), end of induction (Week 24) and at Final Staging (4 weeks after last maintenance dose). Last observation carried forward (LOCF) method was used for missing data. Percentages are based on the number of nonmissing observations within each stratum.

Time frame:
Weeks 12 and 24 and at Final Staging (Week 4 after last maintenance dose)
Reported as:
Number · percentage of participants
Percentage of Participants With the Best Clinical Response by Visit (Clinical Assessment)
percentage of participantsRituximab, Fludarabine, Cyclophosphamide
CR, Week 1241.9 (27.0 to 57.9)
CRu, Week 1216.3 (6.8 to 30.7)
CRi, Week 1216.3 (6.8 to 30.7)
PR, Week 1211.6 (3.9 to 25.1)
PRTox, Week 122.3 (0.1 to 12.3)
SD, Week 120.0 (0.0 to 8.2)
PD, Week 120.0 (0.0 to 8.2)
Not evaluable, Week 1211.6 (3.9 to 25.1)
CR, Week 2430.2 (17.2 to 46.1)
CRu, Week 2411.6 (3.9 to 25.1)
CRi, Week 2437.2 (23.0 to 53.3)
PR, Week 249.3 (2.6 to 22.1)
PRTox, Week 240.0 (0.0 to 8.2)
SD, Week 240.0 (0.0 to 8.2)
PD, Week 240.0 (0.0 to 8.2)
Not evaluable, Week 2411.6 (3.9 to 25.1)
CR, Final staging60.5 (44.4 to 75.0)
CRu, Final staging7.0 (1.5 to 19.1)
CRi, Final staging11.6 (3.9 to 25.1)
PR, Final staging7.0 (1.5 to 19.1)
PRTox, Final staging0.0 (0.0 to 8.2)
SD, Final staging0.0 (0.0 to 8.2)
PD, Final staging2.3 (0.1 to 12.3)
Not evaluable, Final staging11.6 (3.9 to 25.1)
SecondaryPercentage of Participants With the Best Clinical Response by Visit (Clinical + Radiological Assessment)

Best clinical response was determined according to the NCI clinical evaluation and through radiological assessment. CR, CRi, CRu, PR, PRTox, PD, and SD were evaluated. Assessment of response was performed according to the NCI revised guidelines for the diagnosis and treatment of CLL with additional CT scan evaluation of lymphadenopathy during the treatment period (Radiological). Response assessment for interim (Week 12), end of induction (Week 24) and at Final Staging (4 weeks after last maintenance dose). LOCF method was used for missing data. Percentages are based on the number of nonmissing observations within each stratum.

Time frame:
Weeks 12 and 24 and at Final Staging (Week 4 after last maintenance dose)
Reported as:
Number · percentage of participants
Percentage of Participants With the Best Clinical Response by Visit (Clinical + Radiological Assessment)
percentage of participantsRituximab, Fludarabine, Cyclophosphamide
CR, Week 1230.2 (17.2 to 46.1)
CRu, Week 124.7 (0.6 to 15.8)
CRi, Week 127.0 (1.5 to 19.1)
PR, Week 1230.2 (17.2 to 46.1)
PRTox, Week 129.3 (2.6 to 22.1)
SD, Week 1247.0 (1.5 to 19.1)
PD, Week 120.0 (0.0 to 8.2)
Not evaluable, Week 1211.6 (3.9 to 25.1)
CR, Week 2423.3 (11.8 to 38.6)
CRu, Week 247.0 (1.5 to 19.1)
CRi, Week 2430.2 (17.2 to 46.1)
PR, Week 2414.0 (5.3 to 27.9)
PRTox, Week 247.0 (1.5 to 19.1)
SD, Week 247.0 (1.5 to 19.1)
PD, Week 240.0 (0.0 to 8.2)
Not evaluable, Week 2411.6 (3.9 to 25.1)
CR, Final staging48.8 (33.3 to 64.5)
CRu, Final staging7.0 (1.5 to 19.1)
CRi, Final staging7.0 (1.5 to 19.1)
PR, Final staging11.6 (3.9 to 25.1)
PRTox, Final staging2.3 (0.1 to 12.3)
SD, Final staging2.3 (0.1 to 12.3)
PD, Final staging9.3 (2.6 to 22.1)
Not evaluable, Final staging11.6 (3.9 to 25.1)
SecondaryTime to Next Treatment - Percentage of Participants With an Event

Time to next treatment was calculated as the number of days from either discontinuation of the study drug or the administration of the last dose, until the participants needed next treatment.

Time frame:
Weeks 1, 5, 9, 12, 13, 17, 21 and 24 and every 8 weeks for 64 Weeks and every 6 months
Reported as:
Number · percentage of participants
Time to Next Treatment - Percentage of Participants With an Event
percentage of participantsRituximab, Fludarabine, Cyclophosphamide
Time to Next Treatment - Percentage of Participants With an Event37.2
SecondaryTime to Next Treatment - Time to Event

Time to next treatment was calculated as the number of days from either discontinuation of the study drug or the administration of the last dose, until the participants needed next treatment.

Time frame:
Weeks 1, 5, 9, 12, 13, 17, 21 and 24 and every 8 weeks for 64 Weeks and every 6 months
Reported as:
Mean · days
Time to Next Treatment - Time to Event
daysRituximab, Fludarabine, Cyclophosphamide
Time to Next Treatment - Time to Event423.3 ± 398.5
SecondaryPercentage of Participants With Adverse Events (AEs)

AEs were recorded from the date of first medication administration until 28 days after the last trial medication.

Time frame:
Day 1 of Cycles 1, 2, 3, 4, 5, and 6 to 28 days after the last trial medication.
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs)
percentage of participantsRituximab, Fludarabine, Cyclophosphamide
Any AE100
Related AE93.0
Severe AE76.7
SAE62.8
Pregnancy0.0

Adverse events

Collected over Adverse events (AEs) were recorded from the date of first medication administration until 28 days after the last trial medication.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rituximab, Fludarabine, Cyclophosphamide—30/43 (69.8%)36/43 (83.7%)
Most frequent serious events
Showing 10 of 49
Most frequent serious events
EventRituximab, Fludarabine, Cyclophosphamide
PyrexiaGeneral disorders5/43
Febrile neutropeniaBlood and lymphatic system disorders3/43
PneumoniaInfections and infestations2/43
Chest painGeneral disorders2/43
LeukopeniaBlood and lymphatic system disorders2/43
BronchitisInfections and infestations1/43
Cytomegalovirus infectionInfections and infestations1/43
PharyngitisInfections and infestations1/43
Pneumonia primary atypicalInfections and infestations1/43
Postoperative infectionInfections and infestations1/43
Most frequent other events
Showing 10 of 146
Most frequent other events
EventRituximab, Fludarabine, Cyclophosphamide
NeutropeniaBlood and lymphatic system disorders23/43
LeukopeniaBlood and lymphatic system disorders20/43
ThrombocytopeniaBlood and lymphatic system disorders18/43
LymphopeniaBlood and lymphatic system disorders14/43
NauseaGastrointestinal disorders14/43
CoughRespiratory, thoracic and mediastinal disorders14/43
AnaemiaBlood and lymphatic system disorders13/43
DiarrhoeaGastrointestinal disorders10/43
NasopharyngitisInfections and infestations8/43
FatigueGeneral disorders8/43

Baseline characteristics

Intent-To-Treat (ITT) population: all participants who received at least one dose of study medication.

Age, Continuous
Age, Continuous(years)Rituximab, Fludarabine, Cyclophosphamide
Mean61.0 ± 10.1
Sex: Female, Male
Sex: Female, Male(Participants)Rituximab, Fludarabine, Cyclophosphamide
Female14
Male29
08

Study locations

8 sites
  • Tiroler Landeskrankenanstalten Ges.M.B.H.; Innere Medizin Abt. Für Hämatologie & Onkologie
    Innsbruck, 6020, Austria
  • LKH Hochsteiermark; Abt. für Innere Medizin
    Leoben, 8700, Austria
  • Kh Der Barmherzigen Schwestern; Interne I X
    Linz, 4010, Austria
  • A.Ö. Krankenhaus Der Elisabethinen Linz; I. Interne Abt.
    Linz, 4020, Austria
  • Kepler Universitätskliniken GmbH - Med Campus III; I. Medizinische Abteilung
    Linz, 4020, Austria
  • Landeskrankenhaus Rankweil; Interne E
    Rankweil, 6830, Austria
  • Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt.
    Salzburg, 5020, Austria
  • Klinikum Kreuzschwestern Wels; Iii. Interne Abt.
    Wels, 4600, Austria
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2005 to primary completion in Sep 2012, 83 months.

Results were first posted in Sep 2014, 1 year 11 months after primary completion.

Of 41 industry-sponsored phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 87. This study's 83 months is above that.

Counting every sponsor, half of 249 studies reached it within 73 months; a quarter within 41 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2013
First posted
Dec 17, 2013
StartActual
Oct 11, 2005
Primary completionActual
Sep 24, 2012
CompletionActual
Sep 24, 2012
Results first posted
Sep 10, 2014
Last update
Aug 18, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02013817
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 17, 2013
Start date
Oct 11, 2005
Primary completion
Sep 24, 2012
Completion
Sep 24, 2012
Results posted
Sep 10, 2014
Last update
Aug 18, 2017

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion